Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

BIBF 1120 for Recurrent High-Grade Gliomas

This study has been completed.
Sponsor:
Collaborators:
Boehringer Ingelheim
Wake Forest Baptist Health
University of Virginia
Massachusetts General Hospital
The Cleveland Clinic
Information provided by (Responsible Party):
Patrick Y. Wen, MD, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
NCT01380782
First received: June 21, 2011
Last updated: August 15, 2014
Last verified: August 2014

June 21, 2011
August 15, 2014
May 2012
July 2013   (final data collection date for primary outcome measure)
  • 6-Month Progression Free Survival [ Time Frame: Six months ] [ Designated as safety issue: No ]
    To determine the efficacy of BIBF 1120 in bevacizumab-naive participants with recurrent glioblastoma (GBM) as measured by 6-month progression-free survival (PFS6).
  • 3-Month Progression Free Survival [ Time Frame: 3 months ] [ Designated as safety issue: No ]
    To determine the efficacy of BIBF 1120 in bevacizumab-treated participants with recurrent GBM as measured by 3-month progression free survival (PFS3).
  • 6-Month Progression Free Survival [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    To determine the efficacy of BIBF 1120 in bevacizumab-naive participants with recurent glioblastoma (GBM) as measured by 6-month progression-free survival (PFS6).
  • 3-Month Progression Free Survival [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    To determine the efficacy of BIBF 1120 in bevacizumab-treated participants with recurrent GBM as measured by 3-month progression free survival (PFS3).
Complete list of historical versions of study NCT01380782 on ClinicalTrials.gov Archive Site
  • Proportion of Participants Experiencing Stable Disease (SD) as Their Best Radiographic Response [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    Best radiographic response in both populations. There were no participants with partial or complete responses, so the results are being reported in the proportion of participants who experienced stable disease (SD) as their best response (as opposed to progressive disease).
  • Overall Survival [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    Overall survival in both populations
  • Time-to-tumor Progression [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    Time-to-tumor progression in both populations.
  • Safety Profile as Summarized With Descriptive Statistics (Using Toxicity Data Gathered on Trial) [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
    Safety profile in both populations - as adverse events are posted separately in detail, these results will demonstrate serious adverse events (defined as grades 3-5) that were judged at least possibly related to Nintedanib (BIBF 1120).
  • Proportion of participants experiencing complete or partial radiographic response [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    Radiographic response in both populations
  • Overall survival [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    Overall survival in both populations
  • Time-to-tumor Progression [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    Time-to-tumor progression in both populations.
  • Safety Profile as summarized with descriptive statistics (using toxicity data gathered on trial) [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
    Safety profile in both populations
  • Exploratory Objective #1: Progression-free survival at 3- and 6-months for participants with recurrent anaplastic gliomas (AG) [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    To explore the efficacy of BIBF 1120 in bevacizumab-naïve and bevacizumab-treated participants with recurrent anaplastic gliomas (AG)
  • Exploratory Objective #2: Determination if any correlation exists between patient outcomes (survival, PFS3, PFS6) and tumor genotype and/or expression profile [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    To explore the extent to which the tumor's genotype and expression profile correlate with outcome.
  • Exploratory Objective #3: Determination if any correlation exists between patient outcomes (survival, PFS3, PFS6) and serum angiogenic peptides, circulating endothelial cells, and/or circulating progenitor cells [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    To explore the correlation between serum angiogenic peptides, circulating endothelial cells, and circulating progenitor cells with response to therapy.
  • Exploratory Objective #4: Determination if any correlation exists between patient outcomes (survival, PFS3, PFS6) and perfusion MRI, diffusion MRI [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    To explore the correlation between perfusion MRI, diffusion MRI and response to therapy.
  • Exploratory Objective #1: Progression-free Survival at 3- and 6-months for Participants With Recurrent Anaplastic Gliomas (AG) [ Time Frame: Arm A - 6 months; Arm B - 3 months ] [ Designated as safety issue: No ]
    To explore the efficacy of BIBF 1120 in bevacizumab-naïve and bevacizumab-treated participants with recurrent anaplastic gliomas (AG) survival was assessed at 6 months for Arm A and 3 months for Arm B.
  • Exploratory Objective #2: Determination if Any Correlation Exists Between Patient Outcomes (Survival, PFS3, PFS6) and Tumor Genotype and/or Expression Profile [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    To explore the extent to which the tumor's genotype and expression profile correlate with outcome.
  • Exploratory Objective #3: Determination if Any Correlation Exists Between Patient Outcomes (Survival, PFS3, PFS6) and Serum Angiogenic Peptides, Circulating Endothelial Cells, and/or Circulating Progenitor Cells [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    To explore the correlation between serum angiogenic peptides, circulating endothelial cells, and circulating progenitor cells with response to therapy.
  • Exploratory Objective #4: Determination if Any Correlation Exists Between Patient Outcomes (Survival, PFS3, PFS6) and Perfusion MRI, Diffusion MRI [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    To explore the correlation between perfusion MRI, diffusion MRI and response to therapy.
Not Provided
 
BIBF 1120 for Recurrent High-Grade Gliomas
Phase II Trial of Triple Receptor Tyrosine Kinase Receptor Inhibitor BIBF 1120 in Recurrent High-Grade Gliomas

BIBF 1120 is a newly discovered compound that may stop cancer cells from growing abnormally. This drug is currently being used in treatment for other cancers in research studies and information from those other research studies suggests that this agent, BIBF 1120, may help to stop recurrent malignant glioma cells from multiplying and it may also prevent the growth of new blood vessels at the site of the tumor. In this research study, the investigators are looking to see how well BIBF 1120 works in patients with recurrent malignant gliomas.

This is a two arm, multicenter, open label phase II trial in adult patients with recurrent supratentorial high-grade glioma. One arm (the "bevacizumab naïve" arm) will enroll patients who have not received prior bevacizumab therapy, and the other arm (the "post-bevacizumab" arm) will enroll patients who have experienced progression on bevacizumab.

All subjects will receive BIBF 1120 at 200mg orally, twice daily in cycles of 28 days. Subjects will come to the clinic on Day 1 of each cycle (or within 2 days prior) for blood and urine tests and a physical and neurologic exam. Bloods will also be checked within 2 days before or after Day 15 of Cycles 1 and 2. An additional blood sample will be taken on Days 1 and 8 of Cycle 1, at the start of every even-numbered cycle, and at the end of active study treatment. Subjects will have gadolinium-enhanced brain MRI scans performed with tumor measurements at screening, at the start of even-numbered cycles, and at the end of active study treatment(unless already obtained within 4 weeks of completing study treatment). 40 study subjects will have diffusion- and perfusion-weighted MRI at baseline, after 1 week on therapy (± 2 days), within 2 days prior to the start of every even-numbered cycle, and at the end of treatment (unless already obtained within 4 weeks of completing study treatment).

Interventional
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Glioblastoma
  • Gliosarcoma
  • Anaplastic Astrocytoma
  • Anaplastic Oligodendroglioma
  • Anaplastic Oligoastrocytoma
Drug: BIBF 1120
200 mg BID oral for 28 day cycle
  • Experimental: Bevacizumab Naive
    Bevacizumab naive subjects
    Intervention: Drug: BIBF 1120
  • Experimental: Prior Bevacizumab
    Patients previously treated with bevacizumab
    Intervention: Drug: BIBF 1120
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
37
July 2014
July 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Histopathologically-confirmed, supratentorial, recurrent glioblastoma; subjects with an initial diagnosis of a lower grade glioma are eligible if a subsequent biopsy is determined to be glioblastoma
  • Demonstration of recurrent disease on MRI following prior therapy
  • Development of progressive disease after having received prior RT, and must have an interval of at least 12 weeks from the completion of any radiation therapy to study entry (unless progressive tumor growth is outside the radiation field or there is histopathological confirmation of recurrent tumor).
  • Bi-dimensionally measurable disease (minimum measurement of 1 cm in one dimension) on MRI performed within 14 days prior to first treatment. (If receiving corticosteroids, participants must be on a stable or decreasing dose of corticosteroids for at least 5 days prior to baseline MRI.)
  • Life expectancy of at least 12 weeks
  • KPS >/= 60
  • Normal organ and marrow function as defined by protocol
  • Recovered from toxic effects of prior therapy
  • Sufficient tumor availability (at least 15-20 unstained paraffin slides from any prior surgery)

Exclusion Criteria:

  • Receiving other investigational agent
  • More than 2 prior relapses
  • Prior therapy with inhibitor of VEGF, VEGFR, PDGFR, or FGFR (including bevacizumab)
  • Pregnant or breast-feeding
  • Unwilling to agree to adequate contraception, if subject is of child-bearing potential
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to BIBF 1120
  • Use of EIAEDs within 14 days of registration
  • Evidence of recent hemorrhage on baseline MRI of the brain
  • Uncontrolled intercurrent illness
  • Uncontrolled hypertension
  • History of hypertensive encephalopathy
  • History of any of the following within 6 months prior to enrollment: myocardial infarction or unstable angina, stroke or transient ischemic attack, significant vascular disease or peripheral arterial thrombosis, abdominal fistula, gastrointestinal perforation, or intra-abdominal abcess, intracerebral abscess
  • Evidence of bleeding diathesis or coagulopathy
  • Major surgical procedure, open biopsy, or significant traumatic injury within 4 weeks prior to the first treatment day, or anticipation of need for major surgical procedure during the course of the study
  • Minor surgical procedures, stereotactic biopsy, fine needle aspiration, or core biopsy within 7 days prior to the first treatment day
  • Serious non-healing wound, ulcer, or bone fracture
  • History of a different malignancy unless disease-free for at least 5 years (unless cervical cancer in situ, or basal cell or squamous cell carcinoma of the skin)
  • HIV positive
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01380782
11-055, BIBF 1199.94
Yes
Patrick Y. Wen, MD, Dana-Farber Cancer Institute
Patrick Y. Wen, MD
  • Boehringer Ingelheim
  • Wake Forest Baptist Health
  • University of Virginia
  • Massachusetts General Hospital
  • The Cleveland Clinic
Principal Investigator: Patrick Y Wen, M.D. Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
August 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP